AU Patent

AU2021281351A1 — Remdesivir treatment methods

Assigned to Gilead Sciences Inc · Expires 2023-01-19 · 3y expired

What this patent protects

Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula (I), Formula (la), or Formula (lb), or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an …

USPTO Abstract

Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula (I), Formula (la), or Formula (lb), or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021281351A1
Jurisdiction
AU
Classification
—
Expires
2023-01-19
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.